LTR Pharma signed binding ROXUS agreement 8 June, announced 9 June
LTR Pharma has confirmed it disclosed a binding US commercialisation agreement for ROXUS promptly after signing, responding to ASX scrutiny over pre-announcement trading activity.
- Binding agreement with Shed Holdings signed 8 June 2026
- Disclosure made pre-market 9 June 2026, following public holiday
- Company relied on Listing Rule 3.1A during negotiations
- No evidence of confidentiality breach before announcement
- ASX questioned unusual trading ahead of public release
Timing of Binding Agreement and Disclosure
LTR Pharma (ASX:LTP) has clarified the timeline surrounding its binding agreement with Shed Holdings LLC for the US commercialisation of its intranasal erectile dysfunction treatment, ROXUS. The agreement was signed and exchanged at 4:53pm AEST on Monday, 8 June 2026; a national public holiday and non-trading day for the ASX. The company released the information pre-market on Tuesday, 9 June 2026, after securing board approval the previous evening.
Compliance with Continuous Disclosure Obligations
In response to an ASX query dated 11 June, LTR Pharma confirmed it complied with Listing Rule 3.1, which mandates immediate disclosure of material information. The company stated it relied on Listing Rule 3.1A during the negotiation period, which exempts incomplete proposals or negotiations from immediate disclosure. LTR Pharma emphasised that the agreement was incomplete until signed and exchanged, justifying the timing of the announcement.
Market Activity and Confidentiality Concerns
The ASX raised concerns about unusual trading activity in LTR Pharma shares on 5 June 2026, prior to the announcement. The company acknowledged this trading but said it was unaware of any loss of confidentiality or leaks relating to the ROXUS deal before the public release. LTR Pharma also noted an independent broker report circulated on 5 June referencing potential ROXUS commercial agreements, which may have influenced trading patterns.
Context of Prior Market Disclosures
LTR Pharma highlighted that it had previously informed the market of ongoing US commercial discussions for ROXUS in its 28 April 2026 Quarterly Activities Report. The company disclosed that timing was contingent on finalising commercial agreements and onboarding partners via the FDA 503(a) personalised medicine pathway. This ongoing communication framed the eventual announcement as a progression rather than a surprise.
Strategic Significance of the ROXUS Agreement
The binding term sheet with Shed Holdings sets a minimum commercial volume commitment and exclusivity for US telehealth distribution of ROXUS. This deal follows LTR Pharma’s recent arrangement with Strive Specialties as the exclusive US pharmacy fulfilment partner, underscoring a multi-channel commercialisation strategy. These partnerships aim to accelerate ROXUS’s entry into the sizeable US erectile dysfunction market through telehealth and pharmacy networks.
Bottom Line?
While LTR Pharma asserts compliance with disclosure rules, unexplained pre-announcement trading activity leaves questions about market sensitivity ahead of the ROXUS US deal announcement.
Questions in the middle?
- What triggered the unusual trading activity prior to the ROXUS announcement?
- How will the Shed Holdings agreement impact LTR Pharma’s US revenue trajectory?
- Will ASX further investigate market conduct around this disclosure?
